

Application and Evaluation The Effect of Metallic Nanoparticles on Metronidazole Performance as a Novel Technology

Mustafa R. Abdulbaqi¹, Furqan M. Abdulelah¹

¹Department of Pharmaceutics, College of Pharmacy, Al-Bayan University/Iraq*

Received: 05th July, 19; Revised: 08th August, 19, Accepted: 05th September, 19; Available Online: 25th September, 2019

ABSTRACT

Objective: The scope of this study is to evaluate the influence of metal nanoparticles application on pharmaceutical properties and biologic activity of an antifungal drug, metronidazole (MTZ).

Method: Metal nanoparticles used in the study, bismuth sulfide (Bi_2S_3) used as the nanocarriers for metronidazole (MTZ), and they were synthesized by chemical co-precipitation method. Drug loading on Bi_2S_3 nanoparticles, lattice property alteration, and average particle sizes were evaluated using Fourier transform infra-red (FTIR) spectroscopy, atomic force microscopy (AFM), and powder x-ray diffraction (PXRD). The evaluation of the release of MTZ from Bi_2S_3 nanoparticles was carried out using USP type II rotating puddle apparatus. The antimicrobial activity of MTZ before and after loading was carried out by the disc diffusion method against two aerobic gram +ve and one aerobic gram -ve bacteria, in addition to two fungi.

Result: This study showed a successful loading process as well as the particles size reduction of MTZ after loading on Bi_2S_3 nanoparticles. *In vitro* release study showed a significant* increase in solubility and dissolution of MTZ after loading on Bi_2S_3 nanoparticles. MTZ showed a significant* increase in antibacterial (against gram +ve aerobic *staphylococcus aureus* and *bacillus subtilis*) and antifungal (*Candida glabrata* and *Candida tropicalis*) activities after loading process.

Conclusion: Nanotechnology was applied successfully to improve both, solubility and biologic activity of the model drug used, metronidazole (MTZ).

Key words: Nanotechnology, Nanocarriers, Metronidazole (MTZ), Bismuth sulfide (Bi_2S_3) nanoparticles.

International Journal of Pharmaceutical Quality Assurance (2019); DOI: 10.25258/ijpqa.10.3.30

How to cite this article: Abdulbaqi, M.R. and Abdulelah, F.M. (2019). Application and Evaluation The Effect of Metallic Nanoparticles on Metronidazole Performance as a Novel Technology. International Journal of Pharmaceutical Quality Assurance 10(3): 97-104.

Author contribution: This study was self-funded and was written, achieve experimental and analytical work and revised by the author.

Source of support: Nil

Conflict of interest: The author report no conflicts of interest. The author alone are responsible for the content and writing of the paper.

OVERVIEW

Nanotechnology is the control of a matter at dimensions of roughly 1 to 100 nm, providing unique properties of the matter because of its small size.¹ Nanotechnology offers many benefits in medicine such as protecting drugs from degradation,² enhancing solubility of water insoluble or poorly soluble drugs³ as well as increasing efficacy of active ingredient. These benefits help to reduce drug doses which in turn decrease the risk of its side effect and toxicity.⁴ Nanocarriers are nanomaterials being used as a vehicle for another substances, such as drugs,⁵ with a diameter range from 1-100 nm.⁶ They are taken up by target cells more easily than larger molecules, so they can be successfully used as delivery tools for bioactive compounds.⁷ Ideal nanocarriers properties include blood stability, no activation of neutrophils, non-inflammatory, non-immunogenic, non-toxic, non-

thrombogenic, readily biodegradable, reticuloendothelial system avoidance, applicable to different molecules (such as small molecules, peptides, proteins and nucleic acids), inexpensive manufacturing process and scalable.⁸

Among nanoparticles with biomedical advantages are inorganic nanoparticles which include metals (gold, copper, silver, magnesium and iron), metal oxides (iron oxide, zinc oxide, titanium dioxide and cerium oxide) and quantum dots (cadmium selenide and cadmium sulfide).⁹ Metal are unique with various biomedical applications involving drug and gene delivery, highly sensitive diagnostic assays, radiotherapy enhancement and thermal ablation.¹⁰ Metal nanoparticles such as bismuth sulfate (Bi_2S_3) have displayed a wide potential in applications including optics, public health products and catalysis.¹¹ Metronidazole (MTZ) was the design drug used in this study, is a nitroimidazole antimicrobial agent that is widely

*Author for Correspondence: drmustafa1986@yahoo.com

used in the treatment of protozoal and anaerobic infections¹² including *Bacterial vaginosis*, *Giardiasis*, *Clostridium difficile* and *Trichomonas*. MTZ cause bacterial cell death by disruption of DNA's helical structure resulting in bacterial nucleic acid synthesis inhibiting.¹³ It has limited or absent antibacterial activity against aerobic bacteria. MTZ belongs to a biopharmaceutical classification system (BCS) class IV drug with extremely poor water solubility (1 mg/mL) and low permeability. The low solubility of drug lead low absorption and bioavailability.¹⁴ Nanotechnology was here utilized as an attractive approach to overcome the low solubility and bioavailability problems^{15,16} by the reduction in particle size of MTZ and thereby alteration in the concomitant physical and to some extent chemical properties.¹⁷ This study was designed to evaluate the effect of nanotechnology as a novel drug delivery approach using metal nanocarrier (Bi_2S_3 nanoparticles) on the solubility and biological activity of MTZ as model drug. Additionally, MTZ have certain biologic spectrum, thereby improving its biological activity by the use of nanotechnology is a promising approach to reduce their dosing frequency as well as to reduce the amount of drug per each dose to decrease undesirable side effect and to widen their spectrum against different types of microbes that was already had no antimicrobial activity against.

MATERIALS

Metronidazole (JIANGSU YEW PHARMACEUTICAL Co. Limited, China), disodium sulfide ($\text{Na}_2\text{S} \cdot 10\text{H}_2\text{O}$) (THOMAS BAKER Co. Limited, India), bismuth nitrate $\text{Bi}(\text{NO}_3)_3 \cdot 6\text{H}_2\text{O}$ (Qualikems Fine Chem Co. Ltd., India), ethanol $\text{C}_2\text{H}_6\text{O}$ (Sigma Chemical Co. Limited, USA) and dimethyl sulfoxide (DMSO) (Loba Chemie Pvt. Ltd, India) were used in this study.

METHODS

Synthesis of bismuth sulfide (Bi_2S_3) nanoparticles

Bi_2S_3 nanoparticles were prepared by chemical co-precipitation technique as described in 0.1 M aqueous solution $\text{Na}_2\text{S} \cdot 10\text{H}_2\text{O}$ was added at a rate of 10 drops/min onto 0.1 M aqueous solution $\text{Bi}(\text{NO}_3)_3 \cdot 6\text{H}_2\text{O}$ with vigorous stirring (1100 rpm) at 80 °C by a magnetic stirrer (Dragon Lab, USA). The stirring (1100 rpm) was continued after titration at 80 °C for 3 h. Then the black sticky product (final product) was filtered, washed with deionized water, desiccated in a desiccator containing silica gel for 3 days and collected to be evaluated.^{18,19}

Loading of metronidazole on Bi_2S_3 nanoparticles

MTZ was loaded to Bi_2S_3 nanoparticles using incorporation method as described in.²⁰ This method involved the addition of the drug in the last step of nanoparticles synthesis, where 0.1 M of MTZ in ethanol solvent was added by fast dropping to the mixture of bismuth nitrate and sodium sulfide while it is vigorously stirred (1100 rpm) at 80°C. The final product was filtered, washed with deionized water and desiccated for 3 days in a desiccator containing silica gel to be collected and evaluated.²¹

Characterization of metronidazole-loaded Bi_2S_3 nanoparticles

Fourier transform infra-red spectroscopy (FTIR)

To determine the nature of functional groups and the purity of unloaded MTZ as well as loaded MTZ with Bi_2S_3 nanoparticles, samples were evaluated by using fourier transform infra-red spectroscopy (FTIR) instrument (Shimadzu Japan) with spectroscopy ($4000\text{-}500\text{ cm}^{-1}$) using potassium bromide disc.²²

Powder x-ray diffraction (PXRD)

The crystallinity of unloaded MTZ and after loading with Bi_2S_3 nanoparticles was determined by PXRD instrument (Shimadzu, Japan). This was equipped with Cu-K α radiation ($\lambda = 1.54060\text{ \AA}$), voltage (40 Kv) and current (30 mA). The samples were analyzed in scanning speed of ($5^\circ/\text{min}$) and axis $\theta\text{-}2\theta$ with a range of 0 to 60 degrees.²³

Atomic force microscopy

Atomic force microscopy (AFM) (Augestrom advance Inc., USA) was used to determine the particle size, size distribution and shape of nanoparticles by resolving individual particles and groups of particles in three dimensions analysis.²⁴ It was performed for unloaded, loaded MTZ and blank Bi_2S_3 nanoparticles. Powder samples were dissolved in methanol, and few drops of each sample were dropped separately on a silica glass plate and allowed to dry at room temperature to be deposited on the plate, then the deposited film was scanned with AFM instrument.²⁵

The drug loading, drug yield and drug entrapment efficiency percentages

The drug loading percent was calculated as a percentage ratio of the drug weight alone in nanoparticles to the weight of drug loaded with nanoparticles and as follow:

$$\text{Drug loading percent} = \frac{\text{weight of drug in nanoparticles}}{\text{weight of nanoparticles loaded with the drug}} \times 100\%$$

The percent of the drug yield was calculated as a percentage ratio of the nanoparticles weight after drug incorporation with nanoparticles to the weight of nanoparticles and drug fed initially in the reaction before incorporation and as follows.²⁶

$$\text{Drug yield percent} = \frac{\text{weight of nanoparticles after drug incorporation (actual)}}{\text{weight of nanoparticles and drug before incorporation (theoretical)}} \times 100\%$$

The entrapment efficiency percent (% E. E) of the drug was calculated as a percentage ratio of the drug weight in nanoparticles after incorporation to the weight of drug that initially fed in the reaction before incorporation and as follows.²⁷

$$\text{E.E percent} = \frac{\text{weight of drug in nanoparticles after incorporation (actual)}}{\text{weight of drug before incorporation (theoretical)}} \times 100\%$$

In vitro release study

The release of MTZ from Bi_2S_3 nanoparticles was performed using USP type II rotating paddle apparatus (Copley, UK) at $37 \pm 0.5^\circ\text{C}$ with rotating speed of 100 rpm. An equivalent 10 mg of MTZ loaded Bi_2S_3 nanoparticles as well as 10 mg of unloaded MTZ (as control) were dispersed separately in 500 ml of phosphate buffer solution (pH 7.4). Then 5 ml samples

were withdrawn at predetermined time intervals and replaced with the same volume of fresh media after each withdrawal. The withdrawn samples were filtered and the content of MTZ was determined by using UV-visible spectrophotometer (Shimadzu, Japan) at 278 nm, each experiment was analyzed in triplicate.^{28,29}

Biological susceptibility test of MTZ loaded on Bi₂S₃ nanoparticles

The susceptibility test was performed using disc diffusion method to evaluate the biologic activity of MTZ loaded Bi₂S₃ nanoparticles in comparison with unloaded MTZ as well as with blank Bi₂S₃ nanoparticles. Each sample was tested against two types of gram +ve bacteria (*Staphylococcus aureus* and *Bacillus subtilis*) and one type of gram -ve bacteria (*Escherichia coli*) using serial diluted concentrations of 250, 125, 62.5 and 32.25 µg/ml of unloaded MTZ and an equivalent concentration of MTZ loaded with Bi₂S₃ nanoparticles as well as an equivalent fraction of blank Bi₂S₃ nanoparticles present in each concentration of loaded MTZ. The same concentrations were used to evaluate the antifungal activity against two candida fungi species, *Candida glabrata* and *Candida tropicalis*. The samples were dissolved using dimethyl sulfoxide (DMSO) as a solvent. All bacteria species used were cultured in Muller Hinton agar for 24 h at 37 °C for antibacterial susceptibility test,^{30,31} while the two fungi species were cultured in Sabouraud Dextrose agar at 37 °C for 48 h.³²

Statistical analysis

SPSS for windows (version 13, SPSS Inc., Chicago, IL, USA) was the package used for statistical analysis. Statistical

significance for each test (*P* value) of less than 0.05 was dependent. All the experiments were carried out in triplicates and the comparisons of quantitative data obtained from biologic activity of metronidazole (MTZ) were analyzed using one-way and two-way ANOVA tests as well as Student t-test was used for comparison of quantitative data for *in vitro* release, the results were expressed as mean ± standard deviation.

RESULTS

Characterization of metronidazole-loaded Bi₂S₃ nanoparticles

Fourier transform infra-red spectroscopy (FTIR)

FTIR spectrum of pure unloaded MTZ (Figure 1 A) showed bands at 2954 cm⁻¹ and 2837 cm⁻¹ attributed to C-H stretching of methyl group, while band at 3089 cm⁻¹ represent C-H stretching of alkene mono substituted (=CH-). The band at 3211 cm⁻¹ is related to the O-H stretching due to intra molecular hydrogen bonding. For loaded MTZ on Bi₂S₃ nanoparticles FTIR spectra (Figure 1 B), same functional groups of unloaded MTZ are presented with small shifting.³³

Powder x-ray diffraction (PXRD)

For pure unloaded MTZ, x-ray diffraction peaks (Figure 2 A) were appeared in high multiplicity with narrow sharp intense peaks, indicating the highly crystalline property of MTZ molecules lattice. While the diffracted peaks after loading process of MTZ on Bi₂S₃ nanoparticles (Figure 2 B) showed nor intense neither sharp peaks. In addition, the multiplicity of diffracted peaks was largely decreased or diminished.




Figure 1: FTIR of (A) unloaded metronidazole (MTZ) and (B) metronidazole (MTZ) loaded Bi₂S₃ nanoparticles.




Figure 2: XRD of (A) unloaded metronidazole (MTZ), (B) metronidazole (MTZ) loaded Bi_2S_3 nanoparticles and (C) blank Bi_2S_3 nanoparticles.

Atomic force microscopy (AFM)

Images from AFM microscope showed smooth surfaces with fine particle size distribution. Two (2D) and three (3D) dimensions particle size images of MTZ determined by AFM device before (Figure 3 A) and after (Figure 3 B) loading on

Bi_2S_3 nanoparticles were 112.99 nm (representing MTZ only) and 113.23 nm (representing MTZ + Bi_2S_3 nanoparticles as one particle) respectively. The average particle size of blank Bi_2S_3 nanoparticles (Figure 3 C) was found 114.55 nm. Particle size distribution was also measured using AFM




Figure 3: AFM 2D and 3D images of (A) unloaded metronidazole (MTZ), (B) metronidazole (MTZ) loaded Bi_2S_3 nanoparticles and (C) blank Bi_2S_3 nanoparticles.

microscope and displayed almost more pyramidal shaped and more fine distribution of MTZ particles after loading on Bi_2S_3 nanoparticles (Figure 4 B) than that of pure drug (Figure 4 A). Particle size distribution was measured for blank Bi_2S_3 nanoparticles too (Figure 4 C).

The drug loading, drug yield and drug entrapment efficiency percentages

Loaded drug percentage for MTZ on Bi_2S_3 nanoparticles was found 62.72%, while the yield MTZ percentage on Bi_2S_3 nanoparticles was found 68.53%. The entrapped MTZ percentage for was found 93.83%.

In vitro drugs release study

MTZ *in vitro* release from Bi_2S_3 nanoparticles (Figure 5) in phosphate buffer solution (pH 7.4) showed significantly* enhanced dissolution of drugs after loading on Bi_2S_3

nanoparticles in comparison with the dissolution of pure unloaded MTZ before loading process. Where MTZ was completely released (100%) from Bi_2S_3 nanoparticles after 45 min, while unloaded MTZ showed 60% dissolution after the same time of 45 min.

Biological susceptibility test of MTZ loaded on Bi_2S_3 nanoparticles

Antibacterial activity evaluation of MTZ (Table 1) before and after loading process with Bi_2S_3 nanoparticles was performed against gram +ve bacteria *Staphylococcus aureus* and *Bacillus subtilis* using different concentrations as mentioned previously.

The antibacterial activity of MTZ loaded on Bi_2S_3 nanoparticles showed significant* antibacterial activity against gram +ve bacteria *Staphylococcus aureus* at concentration 125 and 250 $\mu\text{g}/\text{ml}$, which was absent at all concentrations used of pure unloaded MTZ. Significant*enhancement in the




Figure 4: AFM particle size distribution of (A) unloaded metronidazole (MTZ), (B) metronidazole (MTZ) loaded Bi_2S_3 nanoparticles and (C) blank Bi_2S_3 nanoparticles.




Figure 5: *In vitro* profile of (A) unloaded metronidazole (MTZ) and (B) metronidazole (MTZ) loaded Bi_2S_3 nanoparticles. Data represent mean ($n=3$) \pm SD.

Table 1: Antibacterial activity of unloaded MTZ, MTZ loaded Bi_2S_3 nanoparticles and blank Bi_2S_3 nanoparticles represented as inhibition zone in milliliter (mm).

Sample	<i>Staphylococcus aureus</i>				<i>Bacillus subtilis</i>				<i>Escherichia coli</i>			
	Concentration $\mu\text{g}/\text{ml}$											
	32.25	62.5	125	250	32.25	62.5	125	250	32.25	62.5	125	250
DMSO	—	—	—	—	—	—	—	—	—	—	—	—
Bi_2S_3 nanoparticles	—	—	—	—	—	—	—	—	—	—	—	—
Pure MTZ	—	—	—	—	—	—	10	10	—	—	—	—
MTZ loaded Bi_2S_3 nanoparticles	—	—	11	13	13	15	19	21	—	—	—	—

Note: MTZ (metronidazole); Bi_2S_3 (bismuth sulfide nanoparticles).

antibacterial activity of MTZ loaded on Bi_2S_3 nanoparticles against gram +ve bacteria *Bacillus subtilis* was found at all concentrations used, in contrast to pure unloaded MTZ which had no antibacterial activity at the concentrations (32.25 and 62.5 $\mu\text{g/ml}$) and significant* improvement in the activity at concentrations 125 and 250 $\mu\text{g/ml}$ after loading process. All tested samples in all concentrations used showed no activity on *Escherichia coli*. Antifungal activity of MTZ loaded Bi_2S_3 nanoparticles (Table 2) was also evaluated against *Candida glabrata* and *Candida tropicalis* and showed significantly* increased activity at all tested concentrations 32.25, 62.5, 125 and 250 $\mu\text{g/ml}$ in comparison with same concentrations of unloaded drug.

DISCUSSION

Fourier transformed infra-red (FTIR) spectrum (Figure 1) of unloaded metronidazole (MTZ) indicated that the loading of MTZ on Bi_2S_3 nanoparticles was achieved physically without any chemical reaction or degradation of the drug, where the main functional groups of unloaded MTZ (Figure 1 A) were found in loaded MTZ on Bi_2S_3 nanoparticles (Figure 1 B) with small shifting.³⁴ The *in vitro* release and dissolution profile of MTZ (Figure 5) was found to be improved significantly* after loading process with complete release of MTZ from Bi_2S_3 nanoparticles after 45 min. On the other hand, the unloaded MTZ showed 60% dissolution after the same time. This might be attributed to the lattice transformation, as indicated by powder x-ray diffraction (PXRD), of unloaded MTZ (Figure 2 A) from crystalline into amorphous structure (Figure 2 B) after loading process that may induce alteration in physical and pharmaceutical properties of the drug.^{35,36} In the *in vitro* release study (Figure 5), the dissolution medium used was phosphate buffer solution (pH 7.4), same pH of plasma, since MTZ- Bi_2S_3 nanoparticles complex was prepared as a final active materials and not as a dosage form. Two and three dimensions images (Figure 3) of MTZ particle sizes before and after loading with Bi_2S_3 nanoparticles using AFM device indicated successful loading process with reduction in particle size of the drug, whereas the sum of average particle sizes of unloaded MTZ (112.99 nm) and blank Bi_2S_3 nanoparticles (114.55 nm) was found much lower than that of loaded drug (113.23 nm).³⁷ This reduction in particle size of MTZ after loading process also contribute to the increased solubility and dissolution profile of MTZ.^{38,39}

In this study, AFM particle size distribution diagram (Figure 4) indicates more even and effective particle size distribution of MTZ loaded Bi_2S_3 nanoparticles than that of unloaded drug. This even distribution of MTZ particles after loading process might contribute to the improved and effective release profile of MTZ from the carrying nanocarrier, Bi_2S_3 nanoparticles. High loading and high yield percentages of MTZ indicate effective and reproducible loading process without losing large fraction of MTZ during loading preparation. The excellent entrapped drug percentage also indicates successful loading process as well as efficient therapeutic response, since the metal nanocarrier (Bi_2S_3 nanoparticles) entrapped and carried enough MTZ to produce the desired antimicrobial effect.⁴⁰ Both antibacterial (against *S. aureus* and *B. subtilis*) and antifungal (against *C. glabrata* and *C. tropicalis*) activities were improved significantly* after loading of MTZ on Bi_2S_3 nanoparticles (as displayed in Table 1 and Table 2). The improved biologic activity of MTZ after loading process could be a result of reduced particle size as confirmed by AFM measurement that lead to increase effective surface area of exposure, where the particle size reduction into nano-size (100 nm) facilitate penetration of drug particles into microbial cell membrane and into targeted organelles thereby providing targeted nanotechnology delivery system of MTZ toward microbial pathogens.^{41,42} The significant* enhancement in the solubility as well as dissolution profile of MTZ might also contribute to the improved biological activity, since the enhanced dissolution of the drug after loading process allowed drug to be released effectively out of Bi_2S_3 nanocarrier that provide more available MTZ in solution to be transported or diffused into the target pathogenic bacteria and fungi.^{43,44} The significant* increase in the solubility of MTZ would expect to improve absorption and hence bioavailability of the prepared MTZ loaded Bi_2S_3 nanoparticles.^{45,46}

CONCLUSION

This study concluded that the use of nanotechnology may offer many benefits in pharmaceutical field. It may enhance the solubility of water insoluble or poorly soluble drugs such as MTZ, as well as increasing the efficacy of its active ingredient. This significant* improvement in pharmaceutical and biological properties by the utilization of nanotechnology permit further future applications using other drugs, such as anticancer drugs that possess serious side and toxic effects on

Table 2: Antifungal activity of unloaded MTZ, MTZ loaded Bi_2S_3 nanoparticles and blank Bi_2S_3 nanoparticles represented as inhibition zone in milliliter (mm).

Sample	<i>Candida glabrata</i>				<i>Candida tropicalis</i>			
	Concentration $\mu\text{g/ml}$							
	32. 25	62. 5	125	250	32. 25	62. 5	125	250
DMSO	—	—	—	—	—	—	—	—
Bi_2S_3 nanoparticles	—	—	7	11	—	—	4	6
Pure MTZ	9	10	11	17	11	12	13	13
MTZ loaded Bi_2S_3 nanoparticles	13	14	40	45	12	17	21	28

Note: MTZ (metronidazole); Bi_2S_3 (bismuth sulfide nanoparticles).

human body and therefore improving drug properties help to reduce drug doses which in turn decrease the risk of its side effects and toxicity.

ACKNOWLEDGEMENT

Special thanks to Al-Bayan University for their support and encouragement. Thanks and appreciation for the central service lab/College of Science/Baghdad University for performing the analytical methods in this study.

REFERENCES

- Guo J-W, Lee Y-H, Huang H-W, Tzou M-C, Wang Y-J, Tsai J-C. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations. *IntJ Nanomed*. 2014;9:4773–83.
- Caban S, Aytekin E, Sahin A, Capan Y. Nanosystems for drug delivery. *OA Drug DesDeli* 2014;2:1-7.
- Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. *JDrug Deli*. 2013;2013:1-15.
- Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing "side effects" of pharmaceuticals on society and the environment. *Sci Total Environ*. 2013;443:324-37.
- Qian W-Y, Sun D-M, Zhu R-R, Du X-L, Liu H, Wang S-L. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. *IntJ Nanomed*. 2012;7:5781-92.
- Kapadi SV, Gadhe L. Recent trend in nanopharmaceuticals: An overview. *World JPharm Res*. 2015;4:553-66.
- Varma JR, Kumar TS, Prasanthi B, Ratna JV. Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: Efficiency for alveolar macrophage targeting. *Indian J. Pharm. Sci*. 2015;77:258.
- Sharma G, Lakkadwala S, Modgil A, Singh J. The role of cell-penetrating peptide and transferrin on enhanced delivery of drug to brain. *Int J Mol Sci*. 2016;17:1-18.
- Nasir A, Kausar A. A review on materials derived from polystyrene and different types of nanoparticles. *Polymer-Plastics TechEngi*. 2015;54:1819-49.
- Shivaramakrishnan B, Gurumurthy B, Balasubramanian A. Potential biomedical applications of metallic nanobiomaterials: a review. *Int J Pharm Sci Res*. 2017;8:985 -1000.
- Pandit S, Dasgupta D, Dewan N, Ahmed P. Nanotechnology based biosensors and its application. *The Pharma Innovation Journal* 2016;5:18-25.
- Senthilkumaran S, Shah S, Balamurugan N, Thirumalaikolundusubramanian P. Metronidazole encephalopathy: Uncommon reaction to a common drug. *IntJCritical illness and injury Sci*. 2015;5:123-4.
- Kalita B, Saikia K, Kalita B. Formulation and evaluation of metronidazole microspheres-loaded bioadhesive vaginal gel. *Asian J Pharm Clin Res* 2017;10:418-24.
- Monica Rao GS, Sheetal Aghav, Manmeet Kumar. Optimization of Metronidazole Emulgel. *JPharm &Pharmaco*. 2013;2013:1-9.
- Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. *The AAPS journal*. 2015;17:1327-40.
- Pawar A. Novel techniques for solubility, dissolution rate and bioavailability enhancement of class II and IV drugs. *Asian JBiomedPharm Sci*. 2012;2:1-9.
- Kc P, Pu M. Antimicrobial and anticancer activity of silver nanoparticles from edible mushroom: a review. *Asian J Pharm Clin Res*. 2017;10:37-40.
- S. Ranjitha SV, G. Rajarajan, J. Marimuthu, S. Natarajan Structural and Optical Properties of Bismuth Sulfide Nanoparticles. *Int J SciRes*. 2012;2012:9-12.
- Arumugam J, ADR, SK, AAI, RLJ, DMAR. Synthesis of Bi₂S₃ Nanostructures : Solvothermal Approach. *Int J ChemTech Res*. 2014;6:2029-31.
- Abdulbaqi MR, Maraie NK, Dawood AH. Loading of Clarithromycin and Paclitaxel on Synthesized CdS/NiO Nanoparticles as Promising Nanocarriers. *Int JPharmPharm Sci*. 2016: 322-33.
- R. A. Mustafa, K. M. Nidhal, Ashour. HD. Loading of clarithromycin and paclitaxel on synthesized CdS/NiO nanoparticles as promising nanocarriers. *Int J Pharm Pharm Sci*. 2016;8:322-33.
- Rani K. Fourier Transform Infrared Spectroscopy (FTIR) Spectral Analysis of BSA Nanoparticles (BSA NPs) and Egg Albumin Nanoparticles (EA NPs). *Res JChem Sci*. 2016;6: 29-36.
- Ganesh M, Ubaidulla U, Hemalatha P, Peng MM, Jang HT. Development of duloxetine hydrochloride loaded mesoporous silica nanoparticles: characterizations and in vitro evaluation. *AAPS PharmSciTech*. 2015;16:944-51.
- Baalousha M, Prasad A, Lead J. Quantitative measurement of the nanoparticle size and number concentration from liquid suspensions by atomic force microscopy. *Enviro Sci: Processes & Impacts*. 2014;16:1338-47.
- Moosa AA, Ridha AM, Al-Kaser M. Process parameters for green synthesis of silver nanoparticles using leaves extract of aloe vera plant. *Int JMultidisciplinary and Current Res*. 2015;3:966-75.
- Ramadan E, Borg T, Abdelghani GM, Saleh NM. Transdermal microneedle-mediated delivery of polymeric lamivudine-loaded nanoparticles. *J PharmTechDrug Res*. 2016;5:1-8.
- Awotwe-Otoo D, Zidan AS, Rahman Z, Habib MJ. Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies. *AAPS PharmSciTech*. 2012;13:611-22.
- Elzatahry A, Eldin M. Preparation and characterization of metronidazole-loaded chitosan nanoparticles for drug delivery application. *Polymers for Adv Tech*. 2008;19:1787-91.
- Ahmed TA. Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation. *IntJ Nanomed*. 2016;11:515–27.
- Kalinowska-Lis U, Felczak A, Chęcińska L, Zawadzka K, Patyna E, Lisowska K, et al. Synthesis, characterization and antimicrobial activity of water-soluble silver (I) complexes of metronidazole drug and selected counter-ions. *Dalton Transactions*. 2015;44:8178-89.
- Isa T, Zakaria ZAB, Rukayadi Y, Mohd Hezmee MN, Jaji AZ, Imam MU, et al. Antibacterial Activity of Ciprofloxacin-Encapsulated Cockle Shells Calcium Carbonate (Aragonite) Nanoparticles and Its Biocompatibility in Macrophage J774A. 1. *IntJ MolSci*. 2016;17:1-17.
- Hussain A, Samad A, Singh S, Ahsan M, Haque M, Faruk A, et al. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation. *Drug Deli*. 2016;23:642-57.

33. Megalai S, Manjula Y, Manonmani K, Kavitha N, Baby N. Metronidazole: A Corrosion Inhibitor for Mild Steel in Aqueous Environment. *Portugaliae Electrochimica Acta*. 2012;30:395-403.
34. Sadiq AA, Abdul Rassol A. Formulation and evaluation of silibinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract. *Int J Pharm Pharm Sci*. 2014;6:55-67.
35. Singh G, Sharma S, Gupta GD. Extensive Diminution of Particle Size and Amorphization of a Crystalline Drug Attained by Eminent Technology of Solid Dispersion: A Comparative Study. *AAPS PharmSciTech*. 2016;1-15.
36. Maniruzzaman M, Lam M, Molina C, Nokhodchi A. Study of the Transformations of Micro/Nano-crystalline Acetaminophen Polymorphs in Drug-Polymer Binary Mixtures. *AAPS PharmSciTech*. 2016;1-10.
37. Kostova B, Ivanova S, Balashev K, Rachev D, Christova D. Evaluation of poly (2-ethyl-2-oxazoline) containing copolymer networks of varied composition as sustained metoprolol tartrate delivery systems. *AAPS PharmSciTech*. 2014;15:939-46.
38. Nekkanti V, Rueda J. Nanoparticles for Improved Delivery of Poorly Soluble Drugs. *J. Drug*. 2016;1:18-27.
39. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. *Acta Pharm Sinica B*. 2015;5:442-53.
40. Sadat T, Kashi J, Eskandarion S, Esfandyari-Manesh M, Mahmoud S, Marashi A, et al. Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. *IntJ Nanomed*. 2012;7:221-34.
41. Wijenayake A, Abayasekara C, Pitawala H, Bandara B. Antimicrobial potential of two traditional herbometallic drugs against certain pathogenic microbial species. *BMC CompAlter Med*. 2016;16:1-13.
42. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. *IntJ Nanomed*. 2017;12:1227-49.
43. Gowardhane AP, Kadam NV, Dutta S. Review on Enhancement of Solubilization Process. *Ameri JDrug DiscDeve*. 2014;4:134-52.
44. Cheung RCF, Ng TB, Wong JH, Chan WY. Chitosan: an update on potential biomedical and pharmaceutical applications. *Marine drugs*. 2015;13:5156-86.
45. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. *Asian J Pharm Sci*. 2015;10:13-23.
46. Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. *Molecules*. 2015;20:18759-76.